Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies
- PMID: 15146430
- DOI: 10.1002/art.20179
Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies
Abstract
Objective: To examine the measurement characteristics of the Childhood Myositis Assessment Scale (CMAS) in children with juvenile idiopathic inflammatory myopathy (juvenile IIM), and to obtain preliminary data on the clinical significance of CMAS scores.
Methods: One hundred eight children with juvenile IIM were evaluated on 2 occasions, 7-9 months apart, using various measures of physical function, strength, and disease activity. Interrater reliability, construct validity, and responsiveness of the CMAS were examined. The minimum clinically important difference (MID) and CMAS scores corresponding to various degrees of physical disability were estimated.
Results: The intraclass correlation coefficient for 26 patients assessed by 2 examiners was 0.89, indicating very good interrater reliability. The CMAS score correlated highly with the Childhood Health Assessment Questionnaire (C-HAQ) score and with findings on manual muscle testing (MMT) (r(s) = -0.73 and 0.73, respectively) and moderately with physician-assessed global disease activity and skin activity, parent-assessed global disease severity, and muscle magnetic resonance imaging (r(s) = -0.44 to -0.61), thereby demonstrating good construct validity. The standardized response mean was 0.81 (95% confidence interval 0.53, 1.09) in patients with at least 0.8 cm improvement on a 10-cm visual analog scale for physician-assessed global disease activity, indicating strong responsiveness. In bivariate regression models predicting physician-assessed global disease activity, MMT remained significant in models containing the CMAS (P = 0.03) while the C-HAQ did not (P = 0.4). Estimates of the MID ranged from 1.5 to 3.0 points on a 0-52-point scale. CMAS scores corresponding to no, mild, mild-to-moderate, and moderate physical disability, respectively, were 48, 45, 39, and 30.
Conclusion: The CMAS exhibits good reliability, construct validity, and responsiveness, and is therefore a valid instrument for the assessment of physical function, muscle strength, and endurance in children with juvenile IIM. Preliminary data on MID and corresponding levels of disability should aid in the clinical interpretation of CMAS scores when assessing patients with juvenile IIM.
Comment in
-
Childhood myositis assessment scale and muscle strength testing in patients with juvenile dermatomyositis: comment on the article by Huber et al.Arthritis Rheum. 2005 Jan;52(1):368; author reply 368-9. doi: 10.1002/art.20757. Arthritis Rheum. 2005. PMID: 15641070 No abstract available.
Similar articles
-
Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.Arthritis Rheum. 1999 Oct;42(10):2213-9. doi: 10.1002/1529-0131(199910)42:10<2213::AID-ANR25>3.0.CO;2-8. Arthritis Rheum. 1999. PMID: 10524696
-
Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group.J Rheumatol. 2001 May;28(5):1106-11. J Rheumatol. 2001. PMID: 11361197
-
Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores.Rheumatology (Oxford). 2007 Aug;46(8):1363-6. doi: 10.1093/rheumatology/kem131. Epub 2007 Jun 14. Rheumatology (Oxford). 2007. PMID: 17569746
-
Defining Clinical Improvement in Adult and Juvenile Myositis.J Rheumatol. 2003 Mar;30(3):603-17. J Rheumatol. 2003. PMID: 12610824 Review.
-
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.Rheumatology (Oxford). 2004 Jan;43(1):49-54. doi: 10.1093/rheumatology/keg427. Epub 2003 Jul 16. Rheumatology (Oxford). 2004. PMID: 12867580 Review.
Cited by
-
Echocardiographic study of juvenile dermatomyositis patients: new insights from speckle-tracking-derived strain.Clin Rheumatol. 2021 Apr;40(4):1497-1505. doi: 10.1007/s10067-020-05418-4. Epub 2020 Sep 28. Clin Rheumatol. 2021. PMID: 32989504
-
Successful use of albuterol in a patient with central core disease and mitochondrial dysfunction.J Inherit Metab Dis. 2010 Dec;33 Suppl 3(Suppl 3):S205-9. doi: 10.1007/s10545-010-9085-7. Epub 2010 May 5. J Inherit Metab Dis. 2010. PMID: 20443062 Free PMC article.
-
A diagnostic challenge: misdiagnosing Blau syndrome as juvenile dermatomyositis in a pediatric patient.Ann Med Surg (Lond). 2023 Jul 22;85(9):4619-4623. doi: 10.1097/MS9.0000000000001090. eCollection 2023 Sep. Ann Med Surg (Lond). 2023. PMID: 37663701 Free PMC article.
-
Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids.J Pediatr. 2010 Feb;156(2):302-7. doi: 10.1016/j.jpeds.2009.09.008. Epub 2009 Oct 28. J Pediatr. 2010. PMID: 19846111 Free PMC article.
-
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis.Ann Rheum Dis. 2013 May;72(5):686-93. doi: 10.1136/annrheumdis-2012-201483. Epub 2012 Jun 26. Ann Rheum Dis. 2013. PMID: 22736096 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical